Clinical trials: Urologic Neoplasms
Hepatocellular Carcinoma, Renal Cell Carcinoma
Genome-wide Association Study to Predict Treatment Response for Molecular Targeted Therapy in Hepatocellular Carcinoma and Renal Cell Carcinoma
All Hepatocellular carcinoma and Renal cell carcinoma patients who receive molecular targeted therapy will be candidates for the study.
- Trial name
- NCT01482520
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Samsung Medical Center
Urologic Neoplasms
Real World Evidence of PD-L1, TMB Prevalence and Efficacy of 1st Line Chemotherapy in These High or Low Population for Stage IV Urothelial Cancer
This study is a multi-center, non-interventional study. Patients' background, treatment pattern, treatment outcome, efficacy will be collected from medical records in Stage IV urotherial (UC) patients.
- Trial name
- YODO (NCT04052113)
- Where
- Japan
- Volunteers
- 152 people
- Sponsor
- AstraZeneca
Multiple Myeloma, Renal Impairment
Study of Pomalidomide to Evaluate the Pharmacokinetics and Safety for Patients With Multiple Myeloma and Impaired Renal Function (POM Renal)
The purpose of this study is to determine the pharmacokinetics (PK) and safety for the combination of pomalidomide (POM) + low-dose dexamethasone (LD- DEX) in subjects with relapsed or refractory Multiple Myeloma (RRMM) and…
- Trial name
- POM Renal (NCT01575925)
- Testing
- 4 mg Oral POM + 40 mg Oral DEX, 2 mg Oral POM + 40 mg Oral DEX
- Where
- 9 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Celgene
Bladder Cancer, Bladder Cancer Stage I
Loop Resection or Cold-cup Biopsy? A Study Comparing the Accuracy of Muscle Samples During Bladder Tumor Surgery
In this report the investigators compared two deep muscle sampling methods (Loop resection and Cold-Cup Biopsy) during endoscopic resection of bladder tumors for patients with suspected bladder cancer in Tygerberg hospital.
- Conditions
- Bladder Cancer, Bladder Cancer Stage I, TURBT
- Trial name
- NCT06796413
- Testing
- Loop Resection or Cold-cup biopsy
- Where
- South Africa
- Volunteers
- 120 people
- Sponsor
- University of Stellenbosch
Catheter Site Discomfort, Complications
Sevoflurane Versus Desflurane for Catheter-related Bladder Discomfort
We want to evaluate the efficacy of the sevoflurane and desflurane for the prevention of catheter-related bladder discomfort.
- Conditions
- Catheter Site Discomfort, Complications, Anesthesia, Urinary Bladder Neoplasms
- Trial name
- NCT02096224
- Testing
- Sevoflurane, Desflurane
- Where
- South Korea
- Volunteers
- 108 people
- Sponsor
- Seoul National University Hospital
Bladder Cancer, Urothelial Carcinoma
Patient-reported Outcomes in Bladder Cancer
Electronic reporting of patient-reported outcomes with alert algorithm will be tested in a randomized trial in bladder cancer patients undergoing chemo- or immunotherapy.
- Trial name
- iBLAD (NCT03584659)
- Testing
- Electronic patient-reported outcomes
- Where
- 4 sites in Denmark
- Volunteers
- 230 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Kidney Neoplasms
Zero Ischemia Robot-Assisted MWA Assisted Suture-less Tumor Enucleation of RCC With T1 Stage
Zero ischemia laparoscopic radio frequency ablation assisted tumor enucleation has been proved to enable tumor excision with relatively better renal function preservation comparing with conventional laparoscopic partial…
- Trial name
- NCT06715878
- Testing
- Zero Ischemia Robot-Assisted Laparoscopic Microwave Ablation Assisted suture-less Enucleation, robotic-assisted laparoscopic partial nephrectomy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- RenJi Hospital
Renal Cell Carcinoma, Renal Tumor
Non-Invasive Diagnostics of Small Renal Masses
NiSAR is a Ph.D. study and consists of three substudies. Renal cancer is one of the most deadly urologic malignancies and accounts for 900 new cases and 300 deaths per year.
- Trial name
- NISar (NCT03667885)
- Testing
- Blood sample, urine sample, Multi planar MRI
- Where
- Denmark
- Volunteers
- 160 people
- Sponsor
- Odense University Hospital
Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma
A Dose Escalation, Safety and Activity Study of CDX-014 in Patients With Renal Cell Carcinoma and Ovarian Clear Cell Carcinoma
This is a study to determine the safety of CDX-014 and effectiveness (how well the drug works).
- Conditions
- Renal Cell Carcinoma (RCC), Clear-cell Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Kidney Neoplasms
- Trial name
- NCT02837991
- Testing
- CDX-014
- Where
- 5 sites in United States
- Volunteers
- 16 people
- Sponsor
- Celldex Therapeutics
Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy
Treatment Expedition With MRI Processing and Optimization for Muscle Invasive Bladder Cancer
The TEMPO-MIBC trial is a phase III, single-center, two-arm, randomized, controlled trial. Its primary objective is to evaluate the efficacy of a simplified diagnostic and treatment pathway for muscle-invasive bladder cancer…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder Cancer Requiring Cystectomy, Bladder Carcinoma, Bladder Neoplasm
- Trial name
- TEMPO-MIBC (NCT07067749)
- Testing
- multiparametric magnetic resonance imaging (mpMRI) of the bladder, Transurethral resection of bladder tumour (TURBt), Circulating tumour DNA levels assessment
- Where
- Italy
- Volunteers
- 92 people
- Sponsor
- University of Rome Tor Vergata
Bladder Cancer
Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer
This phase II trial will study the effectiveness and toxicity of sequential high dose MVAC followed by gemcitabine and cisplatin, as first line treatment in patients with locally advanced or metastatic bladder cancer.
- Trial name
- NCT00635726
- Testing
- Methotrexate, Vinblastine, Doxorubicin
- Where
- 7 sites in Greece
- Volunteers
- 41 people
- Sponsor
- Hellenic Oncology Research Group
Hypertension, Type 2 Diabetes Mellitus
Nanshan Elderly Cohort Study
Objective: The Nanshan Elderly Cohort Study (NECS) aims to investigate the nutritional, as well as other environmental and genetic factors of chronic diseases, such as cardio-metabolic diseases.
- Conditions
- Hypertension, Type 2 Diabetes Mellitus, Cardiovascular Diseases, Stroke
- Trial name
- NECS (NCT03569735)
- Where
- 2 sites in China
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Urinary Bladder Neoplasms
uPAR PET/CT and FDG PET/MRI for Preoperative Staging of Bladder Cancer
The sensitivity and specificity of uPAR PET/CT with the radioligand 68GaNOTA-AE105 and FDG PET/MRI for preoperative detection of regional lymph node metastases in urinary bladder cancer
- Trial name
- NCT02805608
- Testing
- Injection of 68Ga-NOTA-AE105, Injection of 18F-FDG, Positron Emission Tomography and CT
- Where
- Denmark
- Volunteers
- 40 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Carcinoma, Renal Cell, Kidney Neoplasms
Study Evaluating Interferon And CCI-779 In Advanced Renal Cell Carcinoma
The primary objective of this study is efficacy. The primary efficacy endpoint of this study is a comparison of the overall survival of subjects treated with CCI-779 [Temsirolimus], administered intravenously [IV] once weekly and…
- Trial name
- ARCC (NCT00065468)
- Testing
- Interferon Alfa, CCI-779, Interferon Alfa and CCI-779
- Where
- 153 sites in United States, Argentina and 23 more
- Volunteers
- 626 people
- Sponsor
- Pfizer
Renal Cancer
Multiparametric MRI for Diagnosing Small Renal Tumors
Renal cell carcinoma represents annually 3-5% of all new cancer diagnoses. To date, the standard of care for small renal masses is partial nephrectomy.
- Trial name
- IRMK01 (NCT03470285)
- Testing
- Multiparametric MR imaging (mpMRI)
- Where
- 18 sites in France
- Volunteers
- 387 people
- Sponsor
- University Hospital, Bordeaux
Kidney Cancer
Monoclonal Antibody Therapy in Treating Patients With Metastatic Renal Cell Cancer
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
- Trial name
- NCT00057889
- Testing
- ipilimumab
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Bladder Cancer
Safety Study on AdCD40L Gene Therapy for Bladder Cancer
The study objective is to evaluate the feasibility of three instillations of immunostimulating gene therapy (AdCD40L) in patients with urinary bladder cancer.
- Trial name
- NCT00891748
- Testing
- AdCD40L
- Where
- Sweden
- Volunteers
- 12 people
- Sponsor
- Uppsala University
Heart Failure, Coronary Artery Disease
COVID-19 Testing in Underserved and Vulnerable Populations
As part of National Institutes of Health Rapid Acceleration of Diagnostics-Underserved Populations (RADx-UP) program, the goal of the RADxUP study is to develop, test, and evaluate a rapid, scalable capacity building project to…
- Conditions
- Heart Failure, Coronary Artery Disease, Cancer, Chronic Kidney Diseases
- Trial name
- NCT05315908
- Testing
- Community outreach method
- Where
- United States
- Volunteers
- 9,120 people
- Sponsor
- Jesse Nodora
Bladder Cancer, Muscle-Invasive Bladder Carcinoma
Clinical Trial to Evaluate Post-Operative Outcomes of Ureteral Stent vs Ureteral Stent Free Radical Cystectomy
Subjects will be randomized into 2 groups (stent or no stent) prior to radical cystectomy with ileal conduit urinary diversion (RCIC). They will follow the standard of care and be enrolled in the study for 12 months post-op.
- Conditions
- Bladder Cancer, Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma, Pelvic Malignancy
- Trial name
- NCT07234968
- Testing
- Ureteral Stent Placement, No Ureteral Stent, Indocyanine Green with Fluorescence Imaging
- Where
- 2 sites in United States
- Volunteers
- 70 people
- Sponsor
- Thomas Jefferson University
Stage IV Renal Cell Cancer, Recurrent Renal Cell Cancer
BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer
RATIONALE: BAY 56-3722 may stop the growth of cancer cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of BAY 56-3722 in treating patients who have recurrent…
- Trial name
- NCT00040989
- Testing
- BAY 56-3722, enzyme inhibitor therapy
- Where
- 26 sites in United States
- Sponsor
- Jonsson Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.